MiMedx Group, Inc. provided earnings guidance for the full year 2022. For the year, the company expects net sales of its continuing portfolio of products, which were $240.0 million in 2021, to grow 11% to 14% in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.51 USD | -3.10% | -5.53% | -14.37% |
30/04 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
30/04 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.37% | 1.11B | |
-25.17% | 122M | |
-6.89% | 68.14M | |
+1.08% | 58.18M | |
+1.80% | 53.31M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- MiMedx Group, Inc. Provides Earnings Guidance for the Full Year 2022